Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2OGZ5)

• Drug Name: MORIN Drug Info
• Synonyms: morin; 480-16-0; Aurantica; Calico Yellow; Al-Morin; Toxylon Pomiferum; Morin hydrate; 2',3,4',5,7-Pentahydroxyflavone; 2-(2,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; Bois d,Arc; Osage Orange; Osage Orange Extract; Bois d'arc; C.I. Natural Yellow 11; C.I. Natural Yellow 8; Osage Orange Crystals; 3,5,7,2',4'-Pentahydroxyflavone; 3,5,7,2',4'-Pentahydroxyflavonol; 2'-Hydroxypelargidenolon 1522; 2',4',3,5,7-Pentahydroxyflavone; C.I. 75660; Zlut prirodni 11; 2',4',5,7-Tetrahydroxyflavan-3-ol; Bois d'arc [French]

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5281670
  ChEBI ID: CHEBI:75092
  CAS Number: CAS 480-16-0
  TTD Drug ID: DM2OGZ5
  VARIDT Drug ID: DR00652

Molecule-Related Drug Atlas

Drug(s) Targeting Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[3]
biochanin A	DM0HPWY	Discovery agent	N.A.	Investigative	[3]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[3]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[3]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[8]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Obatoclax	DMPF9ZM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
AZD5991	DM7QGHO	Haematological malignancy	2B33.Y	Phase 1	[10]
AMG 176	DM0Q7NO	Acute myeloid leukaemia	2A60	Phase 1	[10]
PRT1419	DMIKE0O	Melanoma	2C30	Phase 1	[11]
ABBV-467	DM87SM9	Multiple myeloma	2A83	Phase 1	[12]
MIK665	DMTUVCG	Acute myeloid leukaemia	2A60	Phase 1	[13]
AMG 397	DM7CNTG	Refractory hematologic malignancy	2A85.5	Phase 1	[14]
PMID27744724-Compound-18	DM73S2C	N. A.	N. A.	Patented	[15]
Indole-based analog 2	DM0NEVC	N. A.	N. A.	Patented	[15]
PMID27744724-Compound-10	DMFKS2P	N. A.	N. A.	Patented	[15]

Drug(s) Targeting Fatty acid synthase (FASN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cerulenin	DM6N4PR	Weight loss	MG43.5	Approved	[16]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[3]
TVB-2640	DM19GUH	Astrocytoma	2A00.0Y	Phase 2	[17]
TVB-2640	DM19GUH	Astrocytoma	2A00.0Y	Phase 2	[18]
FAS1	DMAX2EW	Fungal infection	1F29-1F2F	Preclinical	[19]
FSA2	DMLNRCI	Fungal infection	1F29-1F2F	Preclinical	[19]
biochanin A	DM0HPWY	Discovery agent	N.A.	Investigative	[3]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[3]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[3]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Plasmodium Enoyl-ACP reductase (Malaria fabI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[20]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[21]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[22]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[22]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[3]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[3]
Thiolactomycin	DMBAWDG	Malaria	1F40-1F45	Investigative	[20]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[3]
Diazaborines	DM5UFZX	Discovery agent	N.A.	Investigative	[23]
ISORHAMNETIN	DMQ4Z6E	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[3]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[3]
KAEMPFEROL	DMHEMUB	Discovery agent	N.A.	Investigative	[3]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[3]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[3]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[8]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[3]
ISORHAMNETIN	DMQ4Z6E	Discovery agent	N.A.	Investigative	[3]
NADPH	DM75Q34	Discovery agent	N.A.	Investigative	[24]

Drug(s) Targeting Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conjugated Estrogens	DMLT0E1	Dyspareunia	GA12	Approved	[25]
Trilostane	DMQZ9GF	Cushing disease	5A70	Approved	[26]
ARZOXIFENE	DMOKCVI	Breast cancer	2C60-2C65	Approved	[27]
Estrogen	DMGY0UT	Menopause symptom	GA30.0	Approved	[28]
MF-101	DM8Z0I3	Hepatitis virus infection	1E50-1E51	Phase 3	[29]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[30]
AUS-131	DMUXO3Z	Hot flushes	GA30	Phase 2	[31]
ERB-041	DMCEPUA	Inflammatory bowel disease	DD72	Phase 2	[32]
Erteberel	DMU1XZD	Prostate hyperplasia	GA90	Phase 2	[33]
VG-101	DMAN21O	Menopause symptom	GA30.0	Phase 1/2	[34]

Drug(s) Targeting Urate anion exchanger 1 (URAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lesinurad	DMUR64T	Hyperuricaemia	5C55.Y	Approved	[35]
Dotinurad	DM0UPQJ	Gout	FA25	Phase 3	[36]
URC102	DMY89BN	Gout	FA25	Phase 2	[37]
RDEA-684	DMNWYHD	Gout	FA25	Phase 2	[35]
RDEA3170	DM1TKG4	Hyperuricaemia	5C55.Y	Phase 2	[38]
AR882	DMFGYZ8	Gout	FA25	Phase 2	[39]
Sulfonamide derivative 11	DMJBR86	N. A.	N. A.	Patented	[40]
Cycloalkyl acid derivative 1	DMXMGSP	N. A.	N. A.	Patented	[40]
2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1	DMHYIAV	N. A.	N. A.	Patented	[40]
Tihoacetate derivative 1	DM6QHO0	N. A.	N. A.	Patented	[40]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[41]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[42]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[42]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[43]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[41]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[42]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[44]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[41]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[45]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[41]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[46]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[47]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[48]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[49]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[50]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[51]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[52]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[53]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[54]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[55]

Drug(s) Affected By Apoptotic protease-activating factor 1 (APAF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[56]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[58]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[59]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[61]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[62]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[63]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[64]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[65]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[66]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[67]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[56]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[68]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Selenium	DM25CGV	N. A.	N. A.	Approved	[70]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[66]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[71]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[72]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[71]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[73]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[74]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[75]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[76]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[77]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[78]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[79]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[80]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[81]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[82]

Drug(s) Affected By Serine/threonine-protein kinase Chk2 (CHEK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[83]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[84]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[85]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[86]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[87]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[62]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[88]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[88]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[89]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[90]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[91]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[92]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[93]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[94]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[95]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[96]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[97]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[98]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[99]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[100]

Drug(s) Affected By Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[84]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[101]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[73]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Selenium	DM25CGV	N. A.	N. A.	Approved	[103]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[77]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[104]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[57]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[105]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[106]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[107]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[108]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[109]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[110]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[111]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[112]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[113]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[114]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[115]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[113]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[116]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[117]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[118]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[76]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[119]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[120]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[119]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[121]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[122]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[123]

Drug(s) Affected By Androgen receptor (AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[124]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[124]
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[124]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[125]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[126]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[127]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[128]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[129]
Selenium	DM25CGV	N. A.	N. A.	Approved	[130]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[131]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[132]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[133]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[134]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[135]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[136]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[116]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[137]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[138]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[139]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[140]

Drug(s) Affected By G2/mitotic-specific cyclin-B1 (CCNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[84]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[101]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[141]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Selenium	DM25CGV	N. A.	N. A.	Approved	[103]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[77]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[120]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[142]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[78]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[143]

Drug(s) Affected By Tyrosine-protein phosphatase non-receptor type 1 (PTPN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[87]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[144]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[145]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[65]
Benzoic Acid	DMKB9FI	Alopecia areata	ED70.2	Approved	[146]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[147]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[148]
Seocalcitol	DMKL9QO	Rickets	5B57	Phase 3	[149]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[150]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[151]

Drug(s) Affected By Ribosomal protein S6 kinase beta-1 (RPS6KB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[152]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[153]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[154]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[155]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[156]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[157]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[158]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[160]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[161]

Drug(s) Affected By M-phase inducer phosphatase 3 (CDC25C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[84]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[162]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[163]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[164]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[59]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[165]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[166]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[167]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[88]

Drug(s) Affected By RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[168]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[169]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[98]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[140]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[170]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[155]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[171]
Selenium	DM25CGV	N. A.	N. A.	Approved	[172]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[173]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[174]

Drug(s) Affected By Multidrug resistance-associated protein 1 (ABCC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[175]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[176]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[177]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[178]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[179]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[180]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[181]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[182]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[183]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[183]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[184]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[185]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[141]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[74]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[186]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[187]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[77]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[188]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[120]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[66]

Drug(s) Affected By Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PIK3CB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[185]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[190]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[191]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[145]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[192]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[193]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[136]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[159]

Drug(s) Affected By Serine/threonine-protein kinase mTOR (MTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[194]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[195]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[153]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[154]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[196]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[174]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[197]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[198]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[199]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[200]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[201]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[202]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[203]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[95]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[204]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[205]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[206]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[207]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[208]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[209]

Drug(s) Affected By Tumor necrosis factor ligand superfamily member 6 (FASLG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[189]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[210]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[211]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[212]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[213]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[51]
Fructose	DM43AN2	Vomiting	MD90	Approved	[214]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[215]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[216]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[217]

Drug(s) Affected By Type I iodothyronine deiodinase (DIO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[218]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[163]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[219]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[220]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[221]
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[222]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[223]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[222]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[224]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[225]

Drug(s) Affected By Thyroxine 5-deiodinase (DIO3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[226]
Vemurafenib	DM62UG5	Melanoma	2C30	Approved	[227]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[228]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[89]
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[222]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[226]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[222]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[226]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[229]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[226]

Drug(s) Affected By Caspase-7 (CASP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[230]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[231]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[232]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[233]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[234]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[234]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[57]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[235]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[236]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[237]

Drug(s) Affected By Protein kinase C epsilon type (PRKCE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[238]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[239]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[164]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[240]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[241]
Indomethacin	DMSC4A7	Bursitis		Approved	[242]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[243]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[244]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[193]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[245]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[132]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[209]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[116]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[137]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[246]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[247]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[186]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[162]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[248]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[120]

Drug(s) Affected By Bcl-2-like protein 1 (BCL2L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[98]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[249]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[76]
Selenium	DM25CGV	N. A.	N. A.	Approved	[172]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[250]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[57]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[251]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[252]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[253]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[51]

Drug(s) Affected By FAS-associated death domain protein (FADD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[116]
Selenium	DM25CGV	N. A.	N. A.	Approved	[254]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[235]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[255]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[239]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[165]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[256]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[257]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[258]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[63]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 3 (BIRC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[259]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[209]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[189]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[76]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[57]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[239]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[240]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[260]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[261]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[262]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 2 (BIRC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[259]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[209]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[252]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[263]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[264]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[265]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[266]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[262]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[267]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[268]

Drug(s) Affected By Caspase-10 (CASP10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[189]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[269]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[76]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[72]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[270]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[239]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[51]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[59]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[271]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[272]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 25 (TNFRSF25)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[59]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[273]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[62]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[257]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[191]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[89]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[274]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[90]

Drug(s) Affected By Diablo IAP-binding mitochondrial protein (DIABLO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[275]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[269]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[76]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[276]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[277]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[278]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[279]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[258]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[221]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[65]

Drug(s) Affected By 5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[66]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[163]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[280]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[280]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[280]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[281]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[282]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[66]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[66]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[192]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor beta (ESR2)	TTOM3J0	ESR2_HUMAN	Inhibitor	[2]
Fatty acid synthase (FASN)	TT7AOUD	FAS_HUMAN	Inhibitor	[3]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	TTL53M6	MCL1_HUMAN	Inhibitor	[2]
Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ)	TTHPFTS	Q965D7_PLAFA	Inhibitor	[3]
Plasmodium Enoyl-ACP reductase (Malaria fabI)	TTNX2CS	Q965D5_PLAFA	Inhibitor	[3]
Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG)	TTBE4IR	Q965D6_PLAFA	Inhibitor	[3]
Urate anion exchanger 1 (URAT1)	TTA592U	S22AC_HUMAN	Inhibitor	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)	OT1OG4QZ	AAKB1_HUMAN	Gene/Protein Processing	[5]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Gene/Protein Processing	[6]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[5]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[5]
Apoptotic protease-activating factor 1 (APAF1)	OTJWIVY0	APAF_HUMAN	Gene/Protein Processing	[5]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[7]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Gene/Protein Processing	[5]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Gene/Protein Processing	[5]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[5]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Gene/Protein Processing	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 411).
• [2] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [3] Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
• [4] Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) express... Drug Metab Dispos. 2007 Jun;35(6):981-6.
• [5] Molecular mechanism of anti-cancerous potential of Morin extracted from mulberry in Hela cells. Food Chem Toxicol. 2018 Feb;112:466-475. doi: 10.1016/j.fct.2017.07.002. Epub 2017 Jul 6.
• [6] Effects of resveratrol and other wine polyphenols on the proliferation, apoptosis and androgen receptor expression in LNCaP cells. Actas Urol Esp. 2014 Jul-Aug;38(6):397-404. doi: 10.1016/j.acuro.2014.02.012. Epub 2014 Apr 13.
• [7] Structure-activity relationship and mechanism of flavonoids on the inhibitory activity of P-glycoprotein (P-gp)-mediated transport of rhodamine123 and daunorubicin in P-gp overexpressed human mouth epidermal carcinoma (KB/MDR) cells. Food Chem Toxicol. 2021 Sep;155:112381. doi: 10.1016/j.fct.2021.112381. Epub 2021 Jul 1.
• [8] 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
• [9] Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Clinical pipeline report, company report or official report of Prelude Therapeutics.
• [12] Clinical pipeline report, company report or official report of AbbVie.
• [13] MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443.
• [14] Clinical pipeline report, company report or official report of Amgen.
• [15] Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.
• [16] Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
• [17] Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
• [18] Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118.
• [19] Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
• [20] Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
• [21] Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75.
• [22] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [23] Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97.
• [24] Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem Biophys Res Commun. 2003 Mar 28;303(1):387-92.
• [25] Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85.
• [26] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [27] Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
• [28] Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6.
• [29] MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65.
• [30] Company report (Axcentua)
• [31] S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
• [32] Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
• [33] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986)
• [34] Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536.
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
• [36] Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021 Aug;22(11):1397-1406.
• [37] Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013).
• [38] The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164.
• [39] Clinical pipeline report, company report or official report of Arthrosi Therapeutics
• [40] Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.
• [41] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [42] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [43] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [44] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [45] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [46] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [47] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [48] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [49] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [50] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [51] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [52] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [53] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [54] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [55] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [56] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [57] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [58] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [59] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [60] Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. Biol Pharm Bull. 2018 May 1;41(5):722-732. doi: 10.1248/bpb.b17-00913. Epub 2018 Feb 14.
• [61] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [62] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [63] Ouabain induces apoptotic cell death in human prostate DU 145 cancer cells through DNA damage and TRAIL pathways. Environ Toxicol. 2019 Dec;34(12):1329-1339. doi: 10.1002/tox.22834. Epub 2019 Aug 21.
• [64] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [65] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [66] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [67] Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
• [68] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [69] Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions. BMC Genomics. 2008 Aug 7;9:376.
• [70] Death receptor 5 regulation during selenium-mediated apoptosis in human prostate cancer cells. Cancer Biol Ther. 2002 May-Jun;1(3):287-90. doi: 10.4161/cbt.83.
• [71] Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
• [72] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [73] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [74] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [75] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [76] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [77] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [78] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [79] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [80] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [81] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [82] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
• [83] Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One. 2011;6(12):e28862. doi: 10.1371/journal.pone.0028862. Epub 2011 Dec 15.
• [84] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [85] Direct activation of ATM by resveratrol under oxidizing conditions. PLoS One. 2014 Jun 16;9(6):e97969. doi: 10.1371/journal.pone.0097969. eCollection 2014.
• [86] Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol Sci. 2009 Sep;111(1):120-30. doi: 10.1093/toxsci/kfp136. Epub 2009 Jun 18.
• [87] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [88] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [89] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [90] Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis. 2009 Aug;30(8):1320-9. doi: 10.1093/carcin/bgp138. Epub 2009 Jun 5.
• [91] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [92] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [93] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [94] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [95] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [96] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [97] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [98] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [99] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [100] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [101] G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
• [102] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [103] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [104] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [105] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [106] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [107] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [108] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [109] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [110] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [111] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [112] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [113] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [114] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [115] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [116] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [117] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [118] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [119] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [120] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [121] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [122] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [123] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [124] TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
• [125] Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
• [126] Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
• [127] Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
• [128] Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
• [129] Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
• [130] Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
• [131] Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.
• [132] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [133] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [134] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [135] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [136] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [137] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [138] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [139] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [140] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [141] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [142] Synthesis and antitumor evaluation of nitrovinyl biphenyls: anticancer agents based on allocolchicines. ChemMedChem. 2011 May 2;6(5):859-68. doi: 10.1002/cmdc.201100019. Epub 2011 Apr 6.
• [143] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [144] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [145] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [146] Synthesis, biological activity and structure-activity relationships of new benzoic acid-based protein tyrosine phosphatase inhibitors endowed with insulinomimetic effects in mouse C2C12 skeletal muscle cells. Eur J Med Chem. 2014 Jan;71:112-27. doi: 10.1016/j.ejmech.2013.11.001. Epub 2013 Nov 11.
• [147] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [148] Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. Neurotoxicology. 2015 Sep;50:56-70.
• [149] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
• [150] Coumarins from Angelica decursiva inhibit -glucosidase activity and protein tyrosine phosphatase 1B. Chem Biol Interact. 2016 May 25;252:93-101. doi: 10.1016/j.cbi.2016.04.020. Epub 2016 Apr 13.
• [151] Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
• [152] Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004 Apr 15;103(8):3138-47. doi: 10.1182/blood-2003-05-1543. Epub 2003 Dec 24.
• [153] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [154] EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One. 2011;6(6):e18691. doi: 10.1371/journal.pone.0018691. Epub 2011 Jun 2.
• [155] Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 2009 Aug;110(2):376-88. doi: 10.1093/toxsci/kfp101. Epub 2009 May 18.
• [156] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [157] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [158] SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun. 2004 Nov 12;324(2):471-80. doi: 10.1016/j.bbrc.2004.09.082.
• [159] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [160] D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):96-101. doi: 10.1016/j.bbrc.2009.02.129. Epub 2009 Feb 28.
• [161] Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res. 2003 Nov 15;63(22):7950-8.
• [162] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [163] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [164] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [165] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [166] Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000 Jun 1;60(11):3065-71.
• [167] Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21. doi: 10.1158/0008-5472.CAN-05-4566.
• [168] Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
• [169] Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol Cancer. 2010 Aug 20;9:220.
• [170] Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
• [171] Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015 Mar;35(3):1063-76. doi: 10.1111/liv.12626. Epub 2014 Jul 30.
• [172] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [173] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [174] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [175] Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines. Toxicol Lett. 2015 Jun 15;235(3):189-98. doi: 10.1016/j.toxlet.2015.04.005. Epub 2015 Apr 9.
• [176] Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
• [177] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [178] Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46.
• [179] Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
• [180] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [181] Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
• [182] Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology. 2007 Dec;12(6):511-7. doi: 10.1080/10245330701562535.
• [183] Functional analysis of MRP1 cloned from bovine. FEBS Lett. 2002 Jun 19;521(1-3):211-3. doi: 10.1016/s0014-5793(02)02816-8.
• [184] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [185] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [186] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [187] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [188] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [189] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [190] Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells. Environ Toxicol. 2021 Sep;36(9):1785-1792. doi: 10.1002/tox.23299. Epub 2021 May 27.
• [191] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [192] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [193] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [194] eIF4E is a critical regulator of human papillomavirus (HPV)-immortalized cervical epithelial (H8) cell growth induced by nicotine. Toxicology. 2019 May 1;419:1-10. doi: 10.1016/j.tox.2019.02.017. Epub 2019 Mar 2.
• [195] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [196] Repression of Kisspeptin1 weakens hydrogen peroxide-caused injury in HTR8 cells via adjusting PI3K/AKT/mTOR pathway. J Biochem Mol Toxicol. 2020 May;34(5):e22461. doi: 10.1002/jbt.22461. Epub 2020 Feb 11.
• [197] Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
• [198] Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One. 2012;7(10):e47516. doi: 10.1371/journal.pone.0047516. Epub 2012 Oct 18.
• [199] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [200] Hydroquinone-induced endoplasmic reticulum stress affects TK6 cell autophagy and apoptosis via ATF6-mTOR. Environ Toxicol. 2023 Aug;38(8):1874-1890. doi: 10.1002/tox.23814. Epub 2023 May 6.
• [201] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [202] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [203] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [204] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [205] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [206] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [207] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [208] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [209] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [210] The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
• [211] NF-B potentiates caspase independent hydrogen peroxide induced cell death. PLoS One. 2011 Feb 15;6(2):e16815. doi: 10.1371/journal.pone.0016815.
• [212] Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res. 2000 Feb;45(3):788-94. doi: 10.1016/s0008-6363(99)00369-7.
• [213] Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol Rep. 2011 Feb;25(2):583-91. doi: 10.3892/or.2010.1097. Epub 2010 Dec 10.
• [214] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [215] Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1071-7. doi: 10.1097/01.meg.0000231750.68513.6c.
• [216] Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine. Toxicol In Vitro. 2016 Sep;35:66-76. doi: 10.1016/j.tiv.2016.05.013. Epub 2016 May 26.
• [217] Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol. 2002 Jan;22(1):37-47. doi: 10.1023/a:1014256603539.
• [218] Thyroid organotypic rat and human cultures used to investigate drug effects on thyroid function, hormone synthesis and release pathways. Toxicol Appl Pharmacol. 2012 Apr 1;260(1):81-8. doi: 10.1016/j.taap.2012.01.029. Epub 2012 Feb 8.
• [219] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [220] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [221] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [222] Screening the ToxCast Phase 1, Phase 2, and e1k Chemical Libraries for Inhibitors of Iodothyronine Deiodinases. Toxicol Sci. 2019 Apr 1;168(2):430-442. doi: 10.1093/toxsci/kfy302.
• [223] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [224] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [225] Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid. 2005 Aug;15(8):835-40. doi: 10.1089/thy.2005.15.835.
• [226] Regulation of type III iodothyronine deiodinase expression in human cell lines. Endocrinology. 2006 Dec;147(12):5845-54. doi: 10.1210/en.2006-0590. Epub 2006 Aug 24.
• [227] MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma. Endocr Relat Cancer. 2016 Mar;23(3):135-46. doi: 10.1530/ERC-15-0162.
• [228] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [229] Disturbance of the Dlk1-Dio3 imprinted domain may underlie placental Dio3 suppression and extracellular thyroid hormone disturbance in placenta-derived JEG-3 cells following decabromodiphenyl ether (BDE209) exposure. Toxicology. 2021 Jun 30;458:152837. doi: 10.1016/j.tox.2021.152837. Epub 2021 Jun 21.
• [230] Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment. Pharmaceutics. 2021 Sep 7;13(9):1415. doi: 10.3390/pharmaceutics13091415.
• [231] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [232] A model to identify novel targets involved in oxidative stress-induced apoptosis in human lung epithelial cells by RNA interference. Toxicol In Vitro. 2010 Feb;24(1):310-8. doi: 10.1016/j.tiv.2009.08.008. Epub 2009 Aug 23.
• [233] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [234] Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
• [235] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [236] Simvastatin induces apoptosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010 Jul;95(7):3453-9. doi: 10.1210/jc.2010-0072. Epub 2010 Apr 28.
• [237] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [238] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [239] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [240] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [241] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [242] Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. Gastroenterology. 2000 Mar;118(3):507-14. doi: 10.1016/s0016-5085(00)70256-3.
• [243] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [244] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [245] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [246] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [247] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [248] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [249] Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
• [250] Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
• [251] Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
• [252] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [253] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [254] Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Res. 2007 Sep-Oct;27(5A):3075-82.
• [255] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [256] The role of Fas-FasL-FADD signaling pathway in arsenic-mediated neuronal apoptosis in vivo and in vitro. Toxicol Lett. 2022 Mar 1;356:143-150. doi: 10.1016/j.toxlet.2021.11.012. Epub 2021 Dec 22.
• [257] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [258] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [259] Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
• [260] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [261] Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10.
• [262] The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. doi: 10.1016/j.taap.2020.114915. Epub 2020 Feb 6.
• [263] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [264] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [265] The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
• [266] Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO). Int J Biochem Cell Biol. 2019 Nov;116:105615. doi: 10.1016/j.biocel.2019.105615. Epub 2019 Sep 17.
• [267] Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells. Eur J Haematol. 2005 Sep;75(3):212-20. doi: 10.1111/j.1600-0609.2005.00498.x.
• [268] Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther. 2002 Jul;1(9):667-77.
• [269] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [270] Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica. 2012 Jan;97(1):38-46. doi: 10.3324/haematol.2011.046466. Epub 2011 Sep 20.
• [271] Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem. 2002 Dec 20;277(51):49504-10. doi: 10.1074/jbc.M207836200. Epub 2002 Oct 17.
• [272] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [273] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [274] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [275] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [276] Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. Biochim Biophys Acta. 2010 Apr;1803(4):452-67. doi: 10.1016/j.bbamcr.2009.12.005. Epub 2010 Jan 4.
• [277] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [278] Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice. Apoptosis. 2007 Nov;12(11):2077-87. doi: 10.1007/s10495-007-0116-2. Epub 2007 Aug 16.
• [279] Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G731-8. doi: 10.1152/ajpgi.00150.2005. Epub 2005 Jun 23.
• [280] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [281] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [282] AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-B pathway. Environ Toxicol. 2016 Jul;31(7):866-76. doi: 10.1002/tox.22097. Epub 2014 Dec 24.